Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux EPISEQ SARS-COV-2 Software

BioMérieux has launched EPISEQ SARS-COV-2, a sequencing- and cloud-based software solution to support microbiology labs in identification and reporting from raw sequencing data related to SARS-CoV-2 variants. 

The SARS-CoV-2 EPISEQ application is intended to identify SARS-CoV-2 variants using samples from positive patients. The platform is automatically updated weekly and identifies variants based on international nomenclatures including new variants of concern as defined by the World Health Organization and the US Centers for Disease Control and Prevention. The EPISEQ SARS-COV-2 software is compatible with llumina, Oxford Nanopore, and Thermo Fisher Scientific sequencing platforms and is intended to be easy to use for microbiology labs without bioinformatics knowledge or computing resources. The application also permits the export of viral genome assemblies and mutations in order to facilitate reporting to national public health authorities and for epidemiology studies.

EPISEQ SARS-COV-2 is the third application hosted on the EPISEQ platform, along with EPISEQ CS for bacterial hospital acquired infections and EPISEQ 16S for microbiome analysis.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.